SOLTI-1907 ATREZZO: Targeting hormonal receptor negative (HR-) or PAM50 non-luminal disease with atezolizumab in combination with trastuzumab and vinorelbine in HER2+metastatic breast cancer (MBC)
No Thumbnail Available
Identifiers
Date
2021-09-21
Authors
Ciruelos, E. M.
Pernas, S.
Perello, A.
Lopez, A.
Salvador Bofill, F. J.
Cejalvo, J. M.
Blancas, I.
Ponce Lorenzo, J.
Servitja, S.
Perez, M.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
